The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
Opinion|Videos|March 23, 2026
Promoting Treatment Adherence and Managing AEs in EGFR+ NSCLC
Author(s)Samuel Rosner, MD, Laura Alder, MD
Samuel Rosner, MD, and Laura Alder, MD, discuss AE management and compliance strategies for patients with EGFR-mutated NSCLC.
Advertisement
Samuel Rosner, MD, and Laura Alder, MD, discuss practical strategies for managing treatment-related adverse events and promoting long-term adherence to targeted therapies in EGFR-mutated non–small cell lung cancer. Alder highlights the importance of proactive monitoring and patient education to address common toxicities associated with targeted and combination regimens. Rosner emphasizes that early recognition and management of adverse events are essential to maintaining treatment intensity and optimizing clinical outcomes.
Advertisement
Related to this article
The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
The 2026 amendment adds 40 new recommendations, including active surveillance, office-based treatment, and chemoablation for select recurrent low-grade disease.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
By finding a way to attack the most important human oncogene, KRAS, the UCSF chemical biologist launched a new era in cancer treatment.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
Advertisement
Advertisement
Trending on OncLive
1
INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC
2
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
3
Five Under 5: Top Oncology Videos for the Week of 9/27
4
NDA Submission Is Initiated for Zipalertinib Plus Chemotherapy in Frontline EGFR Exon 20 Insertion+ NSCLC
5